|
Gene: ANO4 |
Gene summary for ANO4 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ANO4 | Gene ID | 121601 |
Gene name | anoctamin 4 | |
Gene Alias | TMEM16D | |
Cytomap | 12q23.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B7Z9Z0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
121601 | ANO4 | ATC13 | Human | Thyroid | ATC | 3.04e-38 | 6.37e-01 | 0.34 |
121601 | ANO4 | ATC5 | Human | Thyroid | ATC | 2.12e-37 | 6.83e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANO4 | SNV | Missense_Mutation | c.2401T>A | p.Tyr801Asn | p.Y801N | Q32M45 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-05-4410-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ANO4 | SNV | Missense_Mutation | novel | c.2786N>G | p.Tyr929Cys | p.Y929C | Q32M45 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-05-4424-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | erlotinib | SD |
ANO4 | SNV | Missense_Mutation | c.1079T>A | p.Met360Lys | p.M360K | Q32M45 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-35-4123-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ANO4 | SNV | Missense_Mutation | rs140890653 | c.1260N>A | p.His420Gln | p.H420Q | Q32M45 | protein_coding | deleterious(0.03) | probably_damaging(0.972) | TCGA-35-5375-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
ANO4 | SNV | Missense_Mutation | c.2759N>T | p.Glu920Val | p.E920V | Q32M45 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-44-3917-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ANO4 | SNV | Missense_Mutation | c.1738N>C | p.Glu580Gln | p.E580Q | Q32M45 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-44-5644-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ANO4 | SNV | Missense_Mutation | novel | c.2694N>G | p.Ile898Met | p.I898M | Q32M45 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-49-AAR4-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxol | PD |
ANO4 | SNV | Missense_Mutation | c.1274G>A | p.Gly425Glu | p.G425E | Q32M45 | protein_coding | tolerated(0.39) | benign(0.17) | TCGA-55-7995-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR | |
ANO4 | SNV | Missense_Mutation | rs148799316 | c.863A>G | p.Asn288Ser | p.N288S | Q32M45 | protein_coding | tolerated(0.59) | probably_damaging(0.996) | TCGA-55-8299-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ANO4 | SNV | Missense_Mutation | rs755195189 | c.623G>T | p.Arg208Met | p.R208M | Q32M45 | protein_coding | tolerated(0.26) | possibly_damaging(0.547) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |